<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942498</url>
  </required_header>
  <id_info>
    <org_study_id>SXF2-8</org_study_id>
    <nct_id>NCT02942498</nct_id>
  </id_info>
  <brief_title>Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome</brief_title>
  <acronym>SXF2-8</acronym>
  <official_title>Clinical Trials Phase III, Double Blind, Crossover to Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Delos Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine vitamin C and vitamin E in combination are&#xD;
      effective in the treatment of cognitive and behavior disorder in children with fragile X&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of vitamin E and vitamin C supplementation has been associated with a lower&#xD;
      prevalence (-78%) and incidence (-64%) of Alzheimer's disease in the elderly population. It&#xD;
      has recently been shown that dietary vitamin E supplementation reduces the production of free&#xD;
      radicals inhibiting NADPH oxidase activity in circulating neutrophils. Another work describes&#xD;
      the inhibition of glutamate release by activated microglia in cell cultures incubated with&#xD;
      vitamin E, effect that can prevent excitotoxicity.&#xD;
&#xD;
      The investigators propose to evaluate the effectiveness of treatment in neurodevelopmental&#xD;
      disorders affected by fragile X syndrome (FXS) with lipophilic compounds antioxidants such as&#xD;
      tocopherol and hydrophilic compounds antioxidants such as ascorbic acid, which regulate&#xD;
      oxidative stress and improve learning and behavioral mouse model and humans.&#xD;
&#xD;
      Our group has positive results in the use of this combination of antioxidants as a treatment&#xD;
      for fragile X syndrome in adolescents. This disease has developed previous clinical trials&#xD;
      with EUDRACT codes: 2009-017837-23 and 2013-004276-35.&#xD;
&#xD;
      The use of the combination of vitamin C and E in the treatment of cognitive and behavioral&#xD;
      disorder in FXS, is patented PCT-050 187 with reference number 2011070875&#xD;
&#xD;
      This combination will be administered as a single oral dose with a total dose of 10mg / kg /&#xD;
      day for each of the vitamins. This dose is maintained within the therapeutic range of both&#xD;
      antioxidants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Autism Treatment Evaluation Checklist (ATEC).</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Clinical Impression (GCI)</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peabody Picture Vocabulary Test (PiVT)</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Battelle developmental inventory screening</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vineland Adaptive Behavior Scales</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event reported</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative Checklist for Autism in Toddlers (Q-Chat) test</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Golberg scale GHQ-28</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality life SF36 test</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological General Well-Being Index</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbance Scale for Children</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>X Fragile Syndrome</condition>
  <arm_group>
    <arm_group_label>Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin C and Vitamin E supplementation 10 mg/kg/ day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C 10mg/Kg Vitamin E 10 mg/Kg</intervention_name>
    <arm_group_label>Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Fragile X syndrome by genetic testing of molecular biology, full mutation&#xD;
             result methylation.&#xD;
&#xD;
          2. Having an older age of 1 year and less than 9 years&#xD;
&#xD;
          3. Having signed the informed consent document before starting their participation in the&#xD;
             trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any advanced, severe or unstable disease.&#xD;
&#xD;
          2. Individuals with other psychiatric diagnosis as the first diagnosis.&#xD;
&#xD;
          3. It have been suffered serious medical problems in the last 12 months.&#xD;
&#xD;
          4. Be taking more than 100 mg of vitamin E or C a day in the last month.&#xD;
&#xD;
          5. Having physical, mental or sensory impairments that prevent the assessment of&#xD;
             effectiveness.&#xD;
&#xD;
          6. Hypersensitivity to any component of the preparation.&#xD;
&#xD;
          7. Liver failure or severe renal or previous history of kidney stones.&#xD;
&#xD;
          8. Any treatment regimen, including treatment with psychotropic drugs and / or&#xD;
             anticonvulsant therapy that has not been stable for a period ≥ 4 weeks before&#xD;
             randomization.&#xD;
&#xD;
          9. Current treatment with more than two psychoactive medications, excluding medication&#xD;
             used specifically for the control of seizures.&#xD;
&#xD;
         10. Hypoprothrombinemia secondary to vitamin K deficiency&#xD;
&#xD;
         11. Sensitivity to any of the compounds of formula treatment.&#xD;
&#xD;
         12. Patients diagnosed with congenital or idiopathic methemoglobinemia for diagnosis of&#xD;
             glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
         13. Use of oral anticoagulants, iron or vitamin A.&#xD;
&#xD;
         14. Forecast initiate or change pharmacological or no pharmacological interventions during&#xD;
             the course of the study.&#xD;
&#xD;
         15. Patients weighing less than 4.2 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yolanda De Diego Otero, Ph D</last_name>
    <email>yolandadediego@ibima.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Regional de Málaga</name>
      <address>
        <city>Malaga</city>
        <state>Málaga</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Pérez Costilla, M.D PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004 Jan;61(1):82-8.</citation>
    <PMID>14732624</PMID>
  </reference>
  <reference>
    <citation>Castilla P, Dávalos A, Teruel JL, Cerrato F, Fernández-Lucas M, Merino JL, Sánchez-Martín CC, Ortuño J, Lasunción MA. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr. 2008 Apr;87(4):1053-61.</citation>
    <PMID>18400731</PMID>
  </reference>
  <reference>
    <citation>Barger SW, Goodwin ME, Porter MM, Beggs ML. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007 Jun;101(5):1205-13. Epub 2007 Mar 30.</citation>
    <PMID>17403030</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>behavior, cognitive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Child Behavior Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

